5535-03-5

Basic information

• Product Name: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester
• Synonyms: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester;Benzoic acid, 4-(oxiranylMethoxy)-, Methyl ester;Methyl 4-(2,3-Epoxypropoxy)benzoate;4-(2,3-epoxypropyloxy)Methyl benzoate
• CAS NO: 5535-03-5
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.21058
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 5535-03-5.mol

Chemical Properties

• Boiling Point: 330.5°C at 760 mmHg
• Flash Point: 146.6°C
• Appearance: /
• Density: 1.213g/cm³
• Vapor Pressure: 0.000166mmHg at 25°C
• Refractive Index: 1.536
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester(5535-03-5)
• EPA Substance Registry System: 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester(5535-03-5)

Safety Data

• Hazardous Substances Data: 5535-03-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester is used as an intermediate for the synthesis of tyrosinase inhibitors, which are essential in the development of medications targeting hyperpigmentation and related skin conditions. These inhibitors help regulate the overproduction of melanin, providing potential therapeutic benefits for individuals affected by skin discoloration and other pigmentation-related issues.
Used in Cosmetics Industry:
In the cosmetics industry, 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester is used as a key component in the formulation of skin lightening products. Its role in the production of tyrosinase inhibitors makes it a valuable addition to creams, lotions, and serums designed to reduce the appearance of dark spots, age spots, and other forms of hyperpigmentation. By incorporating 4-(2-Oxiranylmethoxy)benzoic Acid Methyl Ester into their formulations, cosmetic manufacturers can offer effective solutions for individuals seeking to improve the overall tone and texture of their skin.

InChI:InChI=1/C11H12O4/c1-13-11(12)8-2-4-9(5-3-8)14-6-10-7-15-10/h2-5,10H,6-7H2,1H3

Upstream product

• 99-96-7 4-hydroxy-benzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 106-89-8 epichlorohydrin 

Downstream Products

• 60377-66-4 4-[3-(4-tert-Butyl-phenylamino)-2-hydroxy-propoxy]-benzoic acid 
• 1453205-22-5 methyl 4-[2-hydroxy-3-[methyl(prop-2-ynyl)amino]propoxy]benzoate 
• 1453205-23-6 methyl 4-[2-hydroxy-3-(prop-2-ynylamino)propoxy]benzoate 
• 1453205-28-1 2-[4-[2-hydroxy-3-(prop-2-ynylamino)propoxy]phenyl]acetamide 
• 1453205-27-0 4-[2-hydroxy-3-(prop-2-ynylamino)propoxy]benzamide 
• 35217-95-9 4-(oxiran-2-ylmethoxy)benzoic acid 
• 154871-09-7 methyl 4-[3-(4-nitrophenyl)-2-oxo-5-oxazolidinyl]methoxybenzoate 
• 850339-74-1 4-[2-hydroxy-3-(2-hydroxy-1,1-bishydroxymethyl-ethylamino)-propoxy]-benzoic acid 

Relevant articles and documents

Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity

Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders. As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer. Here, we report on the discovery of new small molecule inhibitors of LSD1 containing a propargylamine warhead, starting out from lysine containing substrate analogues. On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 3. Ethylenediamine Derivatives of (Aryloxy)propanolamines Having Esters on the Aryl Function

Various ethylenediamine derivatives have been incorporated into the nitrogen substituent of certain short-acting (aryloxy)propanolamine systems that contain esters on their aryl functions.Although several of these compounds showed durations of action comparable to their prototypes, most of the nitrogen substituents significantly prolonged the duration of β-adrenergic blockade.Similarly, while one of the compounds showed appreciable cardioselectivity in vitro, generally, little enhancement of cardioselectivity was obtained.A brief discussion of structure-activity relationships observed for the ethylenediamine derivatives is presented.

METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS

A method for the treatment of prophylaxis of cardiac disorders in a mammal, comprising administering to such mammal a short-acting β-blocking compound of the formula: STR1 wherein R may be lower alkyl, aryl, or aralkyl; n may be an integer from 0 to about 10; x may be an integer from 1 to 3; Ar may be substituted or unsubstituted aromatic; R. sub.1 may be lower alkyl, or aralkyl; and pharmaceutically accepted salts thereof. Novel compounds possessing short-acting β-adrenergic blocking activity are also disclosed.

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function

Several short-acting β-adrenergic receptor blocking agents have been prepared by incorporating ester functions into the aryl portion of certain (aryloxy)propanolamine systems.In particular, methyl 3-phenyl>propionate hydrochloride (ASL-8052) was found to be a moderately potent, cardioselective compound with a short duration of action when determined in in vivo canine models.